GILUPI Names Industry Vet as New CEO

SafeHeal Names Former GI Dynamics Exec as CEO

SafeHeal Names Former GI Dynamics Exec as CEO

Dr. Jurinke has about 20 years of biomedical industry experience in technical and commercial positions.

Appointment of Dr. Christian Jurinke as CEO Completes Management Team of GILUPI

Potsdam, (PresseBox) - GILUPI GmbH announces that Dr. Christian Jurinke is appointed to the position of CEO and together with Alexander Herrmann is now managing the company.

Alexander Herrmann, Managing Director of GILUPI, stated „Dr. Jurinke is an accomplished expert when it comes to the development and commercialization of innovative products in the field of cancer molecular diagnostics. Together with Dr. Jurinke we feel well prepared for future projects such as extending our solution platform or further internationalization of our GILUPI CellCollector®.”

Dr. Jurinke has about 20 years of biomedical industry experience in technical and commercial positions. Starting his industry career as a Senior Scientist for Sequenom in Germany, Dr. Jurinke then moved to the USA to serve as Director Product Development and later Director Product Management for Sequenom. He returned to Germany to assume a role as Director Product Management, for start-up Caprotec Bioanalytics, from where he later joined Stratec Molecular as Managing Director. Dr. Jurinke holds a diploma in Biochemistry and Molecular Biology from the University of Hamburg and a doctoral degree in Biochemistry also from the University of Hamburg.

“I am excited and honored to be part of GILUPI a leading company in the field of cancer cell isolation. With the approval of the GILUPI CellCollector® by the European and Chinese authorities we have a strong foundation to build on,” said Dr. Jurinke. “Together with the great and passionate team here at GILUPI we will further extend this platform and develop and commercialize clinically relevant downstream applications for the benefit of cancer patients.”

GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies will become more and more important in tomorrow’s personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly “fishing” them in the patient’s bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE and CFDA approved.

For further information visit www.gilupi.com

MORE ON THIS TOPIC